MedTrace Logo

Insulin Sensitivity in Patients With Atopic Dermatitis

NCT03003793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2019-10-18

Study results available
· View outcomes & findings →

Summary

The incidence of atopic dermatitis and type 2 diabetes, respectively, has increased over many years. Novel research shows an association between the two conditions. While this relationship at least in theory can be explained by lifestyle factors, there is reason to believe that other pathophysiological mechanisms are involved. Hence, our hypothesis is that patients with atopic dermatitis are insulin resistant due to their chronic inflammatory state. Insulin resistance might play an unknown part in the increased frequency of type 2 diabetes among patients with atopic dermatitis. In the present project, the investigators aim to measure insulin sensitivity by means of the 'golden standard' hyperinsulinaemic euglycaemic clamp in patients suffering from atopic dermatitis compared to a healthy control group (matched case-control study). The project is a close collaboration between The Department of Dermatology and Allergy and Center for Diabetes Research at Gentofte Hospital.

Conditions

Interventions

DIAGNOSTIC_TEST

Hyperinsulinemic euglycemic clamp

Hyperinsulinemic euglycemic clamp to detect insulin sensitivity

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · University Hospital, Gentofte

  • Jacob P Thyssen, MD,PhD,DMSc · University Hospital, Gentofte

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-09-30
Completion
2017-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03003793 on ClinicalTrials.gov